The 3rd Annual Psychedelic Therapeutics and Drug Development Conference

Memo

Following the success of the 2nd Annual Psychedelic Therapeutics and Drug Development Conference in 2022, we're thrilled to be hosting the 3rd Annual event on May 15-16, 2023 in Washington, DC. This event has been organized to bring together the world's leading researchers and leaders in academia, industry, the non-profit sector and government to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. This event will highlight the progress being made towards regulatory approval of a variety of psychedelics with the potential to treat various conditions, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder. Our speakers and panelists will be covering important topics such as Clinical Trial Design, Intellectual Property, Regulatory Guidance, Psychedelic Drug Delivery, Commercialization, Legal Issues, Emerging Preclinical Science, and New Clinical Data among other topics. This event has been designed and curated for the benefit of key stakeholders in this burgeoning area and will provide practical guidance, discussion and networking. URL:Tickets: https://go.evvnt.com/1526972-2?pid=5569  Date and Time: On Mon, 15 May 2023 08:00 - Tue, 16 May 2023 15:30 Venue details: Hilton San Francisco Airport Bayfront, 600 Airport Boulevard, Burlingame, California, 94010, United States Prices:Industry: USD 1495.00,Government/Academic/Non-Profit/Clinician: USD 695.00,Graduate Students/Fellows: USD 495.00,Undergraduate Students: USD 395.00 Speakers: Joshua Woolley, MD, Ph.D., Associate Professor, Psychiatry, UCSF Weill Institute for Neurosciences, Gul Dolen, MD, Ph.D., Associate Professor of Neuroscience, Brain Institute, Wendy Klag Center, Johns Hopkins University, Jaspreet Grewal, Chief Executive Officer and Co-Founder, Knowde Group, Bryan Roth, MD, Ph.D., Michael Hooker Distinguished Prof., Pharmacology, Dir., NIMH Psychoactive Drug Screening Program, Eshelman School of Pharmacy, Univ. of North Carolina Chapel Hill, Tim Schlidt, Co-founder and Partner, Palo Santo, Boris Heifets, MD, Ph.D., Assistant Professor of Anesthesiology, Perioperative and Pain Medicine, Stanford University